Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

[Transjugular intrahepatic portosystemic shunt (TIPS)].

M Peck-Radosavljevic1, J Pidlich

  • 1Universitätsklinik für Innere Medizin IV, AKH Wien. markus.peck@akh-wien.ac.at

Wiener Klinische Wochenschrift
|January 6, 2001
PubMed
Summary

Transjugular intrahepatic portosystemic shunt (TIPS) implantation effectively manages portal hypertension complications like variceal bleeding and refractory ascites. Precise indication and contraindication adherence minimizes risks and optimizes outcomes for patients with liver disease.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Impact of patatin-like phospholipase domain containing 3 rs738409 G/G genotype on hepatic decompensation and mortality in patients with portal hypertension.

Alimentary pharmacology & therapeutics·2018
Same author

A multicentre, open-label, phase-I/randomised phase-II study to evaluate safety, pharmacokinetics, and efficacy of nintedanib vs. sorafenib in European patients with advanced hepatocellular carcinoma.

British journal of cancer·2018
Same author

Hepatitis C: The beginning of the end-key elements for successful European and national strategies to eliminate HCV in Europe.

Journal of viral hepatitis·2018
Same author

Carvedilol for reducing portal pressure in primary prophylaxis of variceal bleeding: a dose-response study.

Alimentary pharmacology & therapeutics·2018
Same author

Betablockers do not increase efficacy of band ligation in primary prophylaxis but they improve survival in secondary prophylaxis of variceal bleeding.

Alimentary pharmacology & therapeutics·2018
Same author

Von Willebrand factor indicates bacterial translocation, inflammation, and procoagulant imbalance and predicts complications independently of portal hypertension severity.

Alimentary pharmacology & therapeutics·2018

Area of Science:

  • Interventional Radiology
  • Hepatology
  • Vascular Surgery

Background:

  • Elevated portal pressure, primarily due to cirrhosis, necessitates interventions.
  • Conditions like Budd-Chiari syndrome and portal vein thrombosis also cause portal hypertension.
  • Transjugular intrahepatic portosystemic stent shunt (TIPS) implantation is a key intervention for managing portal hypertension.

Purpose of the Study:

  • To define current indications and contraindications for TIPS implantation.
  • To evaluate the efficacy of TIPS in managing intractable variceal hemorrhage and refractory ascites.
  • To assess the impact of well-defined guidelines on TIPS-related side effects and patient outcomes.

Main Methods:

  • Review of prospective randomized controlled trials (RCTs) on TIPS implantation.

Related Experiment Videos

  • Analysis of patient data regarding indications, contraindications, and outcomes.
  • Evaluation of restenosis rates and management strategies post-TIPS.

    • Main Results:

    • TIPS is indicated for intractable variceal hemorrhage and refractory ascites, improving survival.
    • Primary bleeding prophylaxis is not an indication for TIPS.
    • Contraindications include progressive liver failure, right ventricular decompensation, pulmonary hypertension, and severe hepatic encephalopathy.

    Conclusions:

    • Well-defined indications and contraindications, supported by RCTs, enhance the precise application of TIPS.
    • Adherence to guidelines reduces adverse events and improves patient outcomes in portal hypertension management.
    • TIPS remains a critical therapeutic modality for carefully selected patients with portal hypertension.